Chuang Jen-Zen, Vega Carrie, Jun Wenjin, Sung Ching-Hwa
Department of Ophthalmology, The Margaret M. Dyson Research Institute, New York, NY 10021, USA.
J Clin Invest. 2004 Jul;114(1):131-40. doi: 10.1172/JCI21136.
Retinitis pigmentosa (RP) is a clinically and genetically heterogeneous degenerative eye disease. Mutations at Arg135 of rhodopsin are associated with a severe form of autosomal dominant RP. This report presents evidence that Arg135 mutant rhodopsins (e.g., R135L, R135G, and R135W) are hyperphosphorylated and bind with high affinity to visual arrestin. Mutant rhodopsin recruits the cytosolic arrestin to the plasma membrane, and the rhodopsin-arrestin complex is internalized into the endocytic pathway. Furthermore, the rhodopsin-arrestin complexes alter the morphology of endosomal compartments and severely damage receptor-mediated endocytic functions. The biochemical and cellular defects of Arg135 mutant rhodopsins are distinct from those previously described for class I and class II RP mutations, and, hence, we propose that they be named class III. Impaired endocytic activity may underlie the pathogenesis of RP caused by class III rhodopsin mutations.
视网膜色素变性(RP)是一种临床和遗传异质性的退行性眼病。视紫红质第135位精氨酸(Arg135)的突变与严重的常染色体显性RP相关。本报告提供的证据表明,Arg135突变的视紫红质(如R135L、R135G和R135W)被过度磷酸化,并与视觉抑制蛋白具有高亲和力结合。突变的视紫红质将胞质抑制蛋白招募到质膜,视紫红质-抑制蛋白复合物被内化进入内吞途径。此外,视紫红质-抑制蛋白复合物改变内体区室的形态,并严重损害受体介导的内吞功能。Arg135突变视紫红质的生化和细胞缺陷不同于先前描述的I类和II类RP突变,因此,我们建议将它们命名为III类。内吞活性受损可能是III类视紫红质突变导致RP发病机制的基础。